人体黑色素瘤中线形程序性坏死形成机制的研究
|
摘要
研究目的：
1)对人体石蜡组织标本的回顾性研究,研究人体的黑色素瘤组织中是否存在VM和LPPCN,并分析VM和LPPCN与黑色素瘤患者临床病理参数及预后之间的关系,在此基础上阐述LPPCN和VM在黑色素瘤患者中的临床病理意义；
2)初步研究凋亡相关蛋白在黑色素瘤组织中的表达并分析它们在LPPCN形成中所起的作用,在此基础上进一步探讨LPPCN形成的相关分子机制；
3)研究肿瘤侵袭与转移相关蛋白Twist1、MMP-2、MMP-9在黑色素瘤组织中的表达并分析它们在LPPCN和VM形成过程中所起的作用。
研究方法：
1)收集天津医科大学附属肿瘤医院1996年1月5日-2007年11月26日期间符合实验要求的黑色素瘤标本70例,收集患者的发病年龄、性别、肿瘤大小、发病部位、复发与转移等临床资料,总结分析黑色素瘤患者的临床病理特征；
2)利用HE染色及CD31／PAS双重染色的方法观察70例黑色素瘤组织中是否存在VM和LPPCN,并在显微镜下计数各自的分布情况,用散点图和相关检验法分析LPPCN计数、VM计数、MVD计数之间是否存在相关。并在此基础上进一步分析VM和LPPCN的存在与黑色素瘤患者的临床病理参数及预后之间的关系,LPPCN与VM、内皮依赖性血管之间的关联性；
3)用免疫组化染色的方法检测凋亡相关蛋白在SPPCN细胞、LPPCN细胞及它们周围肿瘤细胞中的表达水平,侵袭与转移相关蛋白MMP-2、MMP-9、Twist1在LPPCN (-)组和LPPCN (+)组、VM(-)组和VM(+)组中的表达水平,用染色指数的方法评价这些蛋白在组间的表达有无差异,并进一步分析这些蛋白的表达在LPPCN和VM形成过程中所起的作用。
结果：
1黑色素瘤组织中存在VM和LPPCN
1.1黑色素瘤组织的形态学观察结果
对黑色素瘤组织进行HE染色和CD31/PAS双重染色结果显示：70例黑色素瘤有33例中存在VM,38例中存在LPPCN,22例中同时存在SPPCN和LPPCN的现象。
1.2 VM和LPPCN与黑色素瘤患者临床病理参数及预后的关系
VM和LPPCN的发生与患者的年龄、性别、肿瘤生长部位、有无黑色素颗粒、复发和远处转移无关(P>0.05),与患者的肿瘤体积有关(P<0.05)。当肿瘤体积大于20.41cm3的时候比较容易发生VM和LPPCN(P<0.05)。Kaplan-Meier生存曲线分析结果显示VM(+)组较VM(-)组、LPPCN(+)组较LPPCN(-)组、VM+LPPCN(+)组较VM+LPPCN(-)组患者的生存时间短,Log-rank检验法比较各组间的生存曲线的差异有统计学意义(P<0.05)。
1.3黑色素瘤组织中VM计数、LPPCN计数与MVD计数之间的关系
VM(+)组MVD计数的平均值高于VM(-)组MVD计数的平均值(P<0.05)。LPPCN(-)组与LPPCN(+)组之间的MVD计数平均值差异比较无统计学意义(P>0.05)。VM+LPPCN(+)组MVD计数的平均值高于VM+LPPCN(-)组MVD计数的平均值(P<0.05)。
2各参数之间相关分析结果
VM计数与LPPCN计数、LPPCN细胞计数之间存在正相关(r=0.469,r=0.470；P=0.024,P=-0.024)。LPPCN计数与LPPCN细胞计数之间存在正相关(r=0.406,P=0.011),肿瘤体积与MVD计数之间存在正相关(r=0.261,P=0.029)。
3凋亡相关蛋白的免疫组化染色结果
3.1线粒体凋亡通路相关蛋白在黑色素瘤组织中的表达
3.1.1 Bcl-2和Bax蛋白在黑色素瘤组织中的表达水平
Bcl-2蛋白在LPPCN(+)组的表达高于LPPCN(-)组的表达(P<0.05)。在LPPCN形成的过程中,早期的SPPCN细胞中Bcl-2蛋白的表达高于晚期LPPCN细胞中Bcl-2蛋白的表达(P<0.05)。早期的SPPCN细胞中Bax蛋白的表达低于晚期LPPCN细胞中Bax蛋白的表达(P<0.05)。早期的SPPCN周围肿瘤细胞中Bcl-2蛋白的表达低于晚期LPPCN周围肿瘤细胞中Bcl-2蛋白的表达(P<0.05)。早期的SPPCN周围肿瘤细胞中Bax蛋白的表达高于晚期LPPCN周围肿瘤细胞中Bax蛋白的表达(P<0.05)。在早期阶段,SPPCN细胞中Bcl-2和Bax蛋白的表达与SPPCN周围肿瘤细胞中Bcl-2和Bax蛋白的表达差异比较无统计学意义(P>0.05)。在晚期阶段,LPPCN细胞中Bcl-2蛋白的表达低于LPPCN周围肿瘤细胞中Bcl-2蛋白的表达(P<0.05)。LPPCN细胞中Bax蛋白的表达高于LPPCN周围肿瘤细胞中Bax蛋白的表达(P<0.05)。
3.1.2 Caspase9和Caspase3蛋白在黑色素瘤组织中的表达
线粒体凋亡途径相关蛋白Caspase9和Caspase3在LPPCN(-)组与LPPCN(+)组之间表达差异比较无统计学意义(P>0.05)。Caspase9和Caspase3蛋白在LPPCN细胞中的表达高于LPPCN周围肿瘤细胞中的表达(P<0.05)。
3.2肿瘤坏死因子家族相关蛋白在黑色素瘤组织中的表达
膜受体凋亡途径相关蛋白TNF、TRAIL、Fas、FasL、Caspase8在LPPCN(-)组与LPPCN (+)组之间表达差异比较无统计学意义(P>0.05)。TNF、TRAIL、Fas、FasL、Caspase8蛋白在LPPCN细胞中的表达与LPPCN周围肿瘤细胞中的表达差异比较无统计学意义(P>0.05)。
4侵袭与转移相关蛋白Twist1、MMP-2、MMP-9的免疫组化染色结果
Twist1蛋白在LPPCN(+)组中的表达高于LPPCN(-)组中的表达(P<0.05),在VM(+)组中的表达高于VM(-)组中的表达(P<0.05),在LPPCN细胞中的表达高于LPPCN周围肿瘤细胞的表达(P<0.05)。MMP-2蛋白在LPPCN(+)组中的表达高于LPPCN (-)组中的表达(P<0.05),在VM(+)组中的表达高于VM(-)组中的表达(P<0.05)。MMP-9蛋白在VM(+)组中的表达高于VM(-)组中的表达(P<0.05)。
结论
1黑色素瘤组织中存在VM和LPPCN,存在VM或／和LPPCN的黑色素瘤患者的临床预后差。VM和LPPCN的发生与患者的年龄、性别、发生部位、有无黑色素颗粒、复发与远处转移无关。当肿瘤的体积>20.41cm3(直径为3cm左右)时容易发生VM和LPPCN.
2 LPPCN是肿瘤细胞为适应环境产生的一种介于凋亡和坏死之间过渡的细胞死亡形式。在缺氧的环境下,部分瘤细胞在线粒体凋亡通路为主的调控下先形成SPPCN,随着缺氧程度的加剧,SPPCN发展为LPPCN。
3黑色素瘤细胞表达的MMP-9、MMP-2、Twistl蛋白都参与了VM形成过程中的细胞形变和基质重塑。肿瘤细胞分泌的PAS阳性物质参与了VM形成中的基质重塑。
Objective:
1) To identify if VM and LPPCN existing in human melanoma through a retrospective study with paraffin tissue samples. To explore the correlation between LPPCN, VM and clinicopathologic factors, clinical prognosis in melanoma'patients. Based on these, to investigate the clinical and pathological significance of VM and LPPCN in melanoma'patients.
2) To disclose the role of apoptosis-associated proteins and analyze relevant molecular mechanism in LPPCN formation.
3) To investigate the expression of Twist1, MMP-2, MMP-9 in melanoma and analyze their role in LPPCN and VM formation.
Methods:
1) 70 melanoma cases undergoing surgery in Tumor Hospital affiliated of Tianjin Medical University from January 1996 to November 2007 were collected in this study. The information of samples including age, gender, tumor size, location, recurrence and metastasis were collected and analyzed the clinicopathologic character of patients.
2) CD31/PAS double staining and HE staining was performed on the slides to confirm the existence of VM and LPPCN. Besides, to count the VM, LPPCN, MVD and analyze the relation between them in melanoma. Based on these, to explore the correlation between LPPCN,VM and clinicopathologic parameter、clinical prognosis in melanoma'patients and investigate the association of LPPCN and VM, endothelium-dependent vessels.
3) Immunohistochemistry method was used to detect the expression of apoptosis-associated proteins in scatter patterned programmed cell necrosis cells, Linearly patterned programmed cell necrosis cells and their circum-tumors cells and the expression of invasive-associated proteins in LPPCN-positive group and LPPCN-negative group, VM-positive group and VM-negative group. Staining index was used to evaluate the difference of these proteins expressed and analyzing their role in VM and LPPCN formation.
Results:
1 VM and LPPCN exists in melanoma
1.1 The morphological observed results in melanoma
CD31/PAS double staining and HE staining shows 33 cases existed VM and 38 cases existed LPPCN in 70 cases melanoma. Besides,22 cases existed SPPCN and LPPCN.
1.2 The relation between LPPCN、VM and clinicopathologic data in melanoma
The occurrence of VM and LPPCN was not correlated with age, gender, location, melanin pigment recurrence and metastasis (P>0.05).The melanoma was prone to generate VM and LPPCN when its volume exceed 20.41cm3(P<0.05) Kaplan-Meier survive plot shows the survive time of VM-positive group was shorter than VM-negative group, the survive time of LPPCN-positive group was shorter than LPPCN-negative group, the survive time of VM and LPPCN-positive group was shorter than VM and LPPCN-negative group (P<0.05)。
1.3 The relation between LPPCN、VM and MVD counting in melanoma
The average MVD counting in VM-positive group was higher than that VM-negative group (P<0.05). The average MVD counting in VM and LPPCN-positive group was higher than that VM and LPPCN-negative group (P<0.05)
2 The correlation results of every parameter
There is a highly positive correlation between the number of VM and the number of LPPCN, the number of LPPCN cells (r=0.469, r=0.470;P=0.024, P=0.024). There is a highly positive correlation between the number of LPPCN and the number of LPPCN cells (r=0.406, P=0.011).There is a highly positive correlation between the size of tumor and the number of endothelium-dependent vessels(r=0.261, P=0.029).
3 The immunohistochemisty staining results of apoptosis-associated proteins
3.1 The expression of mitochondrial-mediating apoptosis relative proteins
3.1.1 The expression of Bcl-2 and Bax in melanoma
The expression of Bcl-2 in LPPCN-positive group was higher than LPPCN--negative group (P<0.05).The expression of Bcl-2 in SPPCN cells was higher than LPPCN cells (P<0.05). The expression of Bax in SPPCN cells was lower than LPPCN cells (P<0.05). The expression of Bcl-2 in SPPCN circum-tumors cells was lower than LPPCN circum-tumors cells (P<0.05). The expression of Bax in SPPCN circum-tumors cells was higher than LPPCN circum-tumors cells (P<0.05). The expression of Bcl-2 in LPPCN cells was lower than LPPCN circum-tumors cells (P<0.05). The expression of Bax in LPPCN cells was higher than LPPCN circum-tumors cells (P<0.05)。
3.1.2 The expression of Caspase9 and Caspase3 in melanoma
The expression of Caspase9 and Caspase3 in LPPCN cells was higher than LPPCN circum-tumors cells(P<0.05). The expression of Caspase9 and Caspase3 in LPPCN-negative group and LPPCN-positive group had not statistical significance (P>0.05).
3.2 The expression of tumor necrosis factor family-mediating apoptosis relative-proteins in melanoma
The expression of TNF, TRAIL, Fas, FasL,Caspase8 in LPPCN-negative group and LPPCN-positive group had not statistical significance(.P>0.05). The expression of TNF, TRAIL, Fas, FasL, Caspase8 in LPPCN cells and LPPCN circum-tumors cells had not statistical significance (P>0.05)
4 The expression of Twist1,MMP2,MMP-9 in melanoma
The expression of Twistl in LPPCN-positive group was higher than LPPCN-negative group (P<0.05).The expression of Twist1 in VM-positive group was higher than VM-negative group (P<0.05). The expression of Twist1 in LPPCN cells was higher than LPPCN circum-tumors cells (P<0.05).The expression of MMP-2 and MMP-9 in VM-positive group was higher than VM-negative group (P<0.05). The expression of MMP-2 in LPPCN-positive group was higher than LPPCN-negative group (P<0.05)
Conclusion:
1 VM and LPPCN existed in melanoma and the patients with VM or/and LPPCN has worse clinical prognosis than those without VM and LPPCN. The occurrence of VM and LPPCN was not correlated with age, gender, location, melanin pigment, recurrence and metastasis. The melanoma was prone to generate VM and LPPCN when its volume exceeds 20.41cm3 (diameters about 3 mm).
2 LPPCN is a transitive cells'dead way between apoptosis and necrosis. Under the genes control of mitochondrial-mediating apoptosis, some melanoma cells underwent SPPCN by hypoxic condition. SPPCN will develop LPPCN when tumor tissue lacks oxygen severely.
3 The proteins of MMP-9,MMP-2,Twist1 expressed by melanoma play a important role in VM formation. The melanoma cells could secrete PAS matter and it participates stromatic remodeling of VM.
1)对人体石蜡组织标本的回顾性研究,研究人体的黑色素瘤组织中是否存在VM和LPPCN,并分析VM和LPPCN与黑色素瘤患者临床病理参数及预后之间的关系,在此基础上阐述LPPCN和VM在黑色素瘤患者中的临床病理意义；
2)初步研究凋亡相关蛋白在黑色素瘤组织中的表达并分析它们在LPPCN形成中所起的作用,在此基础上进一步探讨LPPCN形成的相关分子机制；
3)研究肿瘤侵袭与转移相关蛋白Twist1、MMP-2、MMP-9在黑色素瘤组织中的表达并分析它们在LPPCN和VM形成过程中所起的作用。
研究方法：
1)收集天津医科大学附属肿瘤医院1996年1月5日-2007年11月26日期间符合实验要求的黑色素瘤标本70例,收集患者的发病年龄、性别、肿瘤大小、发病部位、复发与转移等临床资料,总结分析黑色素瘤患者的临床病理特征；
2)利用HE染色及CD31／PAS双重染色的方法观察70例黑色素瘤组织中是否存在VM和LPPCN,并在显微镜下计数各自的分布情况,用散点图和相关检验法分析LPPCN计数、VM计数、MVD计数之间是否存在相关。并在此基础上进一步分析VM和LPPCN的存在与黑色素瘤患者的临床病理参数及预后之间的关系,LPPCN与VM、内皮依赖性血管之间的关联性；
3)用免疫组化染色的方法检测凋亡相关蛋白在SPPCN细胞、LPPCN细胞及它们周围肿瘤细胞中的表达水平,侵袭与转移相关蛋白MMP-2、MMP-9、Twist1在LPPCN (-)组和LPPCN (+)组、VM(-)组和VM(+)组中的表达水平,用染色指数的方法评价这些蛋白在组间的表达有无差异,并进一步分析这些蛋白的表达在LPPCN和VM形成过程中所起的作用。
结果：
1黑色素瘤组织中存在VM和LPPCN
1.1黑色素瘤组织的形态学观察结果
对黑色素瘤组织进行HE染色和CD31/PAS双重染色结果显示：70例黑色素瘤有33例中存在VM,38例中存在LPPCN,22例中同时存在SPPCN和LPPCN的现象。
1.2 VM和LPPCN与黑色素瘤患者临床病理参数及预后的关系
VM和LPPCN的发生与患者的年龄、性别、肿瘤生长部位、有无黑色素颗粒、复发和远处转移无关(P>0.05),与患者的肿瘤体积有关(P<0.05)。当肿瘤体积大于20.41cm3的时候比较容易发生VM和LPPCN(P<0.05)。Kaplan-Meier生存曲线分析结果显示VM(+)组较VM(-)组、LPPCN(+)组较LPPCN(-)组、VM+LPPCN(+)组较VM+LPPCN(-)组患者的生存时间短,Log-rank检验法比较各组间的生存曲线的差异有统计学意义(P<0.05)。
1.3黑色素瘤组织中VM计数、LPPCN计数与MVD计数之间的关系
VM(+)组MVD计数的平均值高于VM(-)组MVD计数的平均值(P<0.05)。LPPCN(-)组与LPPCN(+)组之间的MVD计数平均值差异比较无统计学意义(P>0.05)。VM+LPPCN(+)组MVD计数的平均值高于VM+LPPCN(-)组MVD计数的平均值(P<0.05)。
2各参数之间相关分析结果
VM计数与LPPCN计数、LPPCN细胞计数之间存在正相关(r=0.469,r=0.470；P=0.024,P=-0.024)。LPPCN计数与LPPCN细胞计数之间存在正相关(r=0.406,P=0.011),肿瘤体积与MVD计数之间存在正相关(r=0.261,P=0.029)。
3凋亡相关蛋白的免疫组化染色结果
3.1线粒体凋亡通路相关蛋白在黑色素瘤组织中的表达
3.1.1 Bcl-2和Bax蛋白在黑色素瘤组织中的表达水平
Bcl-2蛋白在LPPCN(+)组的表达高于LPPCN(-)组的表达(P<0.05)。在LPPCN形成的过程中,早期的SPPCN细胞中Bcl-2蛋白的表达高于晚期LPPCN细胞中Bcl-2蛋白的表达(P<0.05)。早期的SPPCN细胞中Bax蛋白的表达低于晚期LPPCN细胞中Bax蛋白的表达(P<0.05)。早期的SPPCN周围肿瘤细胞中Bcl-2蛋白的表达低于晚期LPPCN周围肿瘤细胞中Bcl-2蛋白的表达(P<0.05)。早期的SPPCN周围肿瘤细胞中Bax蛋白的表达高于晚期LPPCN周围肿瘤细胞中Bax蛋白的表达(P<0.05)。在早期阶段,SPPCN细胞中Bcl-2和Bax蛋白的表达与SPPCN周围肿瘤细胞中Bcl-2和Bax蛋白的表达差异比较无统计学意义(P>0.05)。在晚期阶段,LPPCN细胞中Bcl-2蛋白的表达低于LPPCN周围肿瘤细胞中Bcl-2蛋白的表达(P<0.05)。LPPCN细胞中Bax蛋白的表达高于LPPCN周围肿瘤细胞中Bax蛋白的表达(P<0.05)。
3.1.2 Caspase9和Caspase3蛋白在黑色素瘤组织中的表达
线粒体凋亡途径相关蛋白Caspase9和Caspase3在LPPCN(-)组与LPPCN(+)组之间表达差异比较无统计学意义(P>0.05)。Caspase9和Caspase3蛋白在LPPCN细胞中的表达高于LPPCN周围肿瘤细胞中的表达(P<0.05)。
3.2肿瘤坏死因子家族相关蛋白在黑色素瘤组织中的表达
膜受体凋亡途径相关蛋白TNF、TRAIL、Fas、FasL、Caspase8在LPPCN(-)组与LPPCN (+)组之间表达差异比较无统计学意义(P>0.05)。TNF、TRAIL、Fas、FasL、Caspase8蛋白在LPPCN细胞中的表达与LPPCN周围肿瘤细胞中的表达差异比较无统计学意义(P>0.05)。
4侵袭与转移相关蛋白Twist1、MMP-2、MMP-9的免疫组化染色结果
Twist1蛋白在LPPCN(+)组中的表达高于LPPCN(-)组中的表达(P<0.05),在VM(+)组中的表达高于VM(-)组中的表达(P<0.05),在LPPCN细胞中的表达高于LPPCN周围肿瘤细胞的表达(P<0.05)。MMP-2蛋白在LPPCN(+)组中的表达高于LPPCN (-)组中的表达(P<0.05),在VM(+)组中的表达高于VM(-)组中的表达(P<0.05)。MMP-9蛋白在VM(+)组中的表达高于VM(-)组中的表达(P<0.05)。
结论
1黑色素瘤组织中存在VM和LPPCN,存在VM或／和LPPCN的黑色素瘤患者的临床预后差。VM和LPPCN的发生与患者的年龄、性别、发生部位、有无黑色素颗粒、复发与远处转移无关。当肿瘤的体积>20.41cm3(直径为3cm左右)时容易发生VM和LPPCN.
2 LPPCN是肿瘤细胞为适应环境产生的一种介于凋亡和坏死之间过渡的细胞死亡形式。在缺氧的环境下,部分瘤细胞在线粒体凋亡通路为主的调控下先形成SPPCN,随着缺氧程度的加剧,SPPCN发展为LPPCN。
3黑色素瘤细胞表达的MMP-9、MMP-2、Twistl蛋白都参与了VM形成过程中的细胞形变和基质重塑。肿瘤细胞分泌的PAS阳性物质参与了VM形成中的基质重塑。
Objective:
1) To identify if VM and LPPCN existing in human melanoma through a retrospective study with paraffin tissue samples. To explore the correlation between LPPCN, VM and clinicopathologic factors, clinical prognosis in melanoma'patients. Based on these, to investigate the clinical and pathological significance of VM and LPPCN in melanoma'patients.
2) To disclose the role of apoptosis-associated proteins and analyze relevant molecular mechanism in LPPCN formation.
3) To investigate the expression of Twist1, MMP-2, MMP-9 in melanoma and analyze their role in LPPCN and VM formation.
Methods:
1) 70 melanoma cases undergoing surgery in Tumor Hospital affiliated of Tianjin Medical University from January 1996 to November 2007 were collected in this study. The information of samples including age, gender, tumor size, location, recurrence and metastasis were collected and analyzed the clinicopathologic character of patients.
2) CD31/PAS double staining and HE staining was performed on the slides to confirm the existence of VM and LPPCN. Besides, to count the VM, LPPCN, MVD and analyze the relation between them in melanoma. Based on these, to explore the correlation between LPPCN,VM and clinicopathologic parameter、clinical prognosis in melanoma'patients and investigate the association of LPPCN and VM, endothelium-dependent vessels.
3) Immunohistochemistry method was used to detect the expression of apoptosis-associated proteins in scatter patterned programmed cell necrosis cells, Linearly patterned programmed cell necrosis cells and their circum-tumors cells and the expression of invasive-associated proteins in LPPCN-positive group and LPPCN-negative group, VM-positive group and VM-negative group. Staining index was used to evaluate the difference of these proteins expressed and analyzing their role in VM and LPPCN formation.
Results:
1 VM and LPPCN exists in melanoma
1.1 The morphological observed results in melanoma
CD31/PAS double staining and HE staining shows 33 cases existed VM and 38 cases existed LPPCN in 70 cases melanoma. Besides,22 cases existed SPPCN and LPPCN.
1.2 The relation between LPPCN、VM and clinicopathologic data in melanoma
The occurrence of VM and LPPCN was not correlated with age, gender, location, melanin pigment recurrence and metastasis (P>0.05).The melanoma was prone to generate VM and LPPCN when its volume exceed 20.41cm3(P<0.05) Kaplan-Meier survive plot shows the survive time of VM-positive group was shorter than VM-negative group, the survive time of LPPCN-positive group was shorter than LPPCN-negative group, the survive time of VM and LPPCN-positive group was shorter than VM and LPPCN-negative group (P<0.05)。
1.3 The relation between LPPCN、VM and MVD counting in melanoma
The average MVD counting in VM-positive group was higher than that VM-negative group (P<0.05). The average MVD counting in VM and LPPCN-positive group was higher than that VM and LPPCN-negative group (P<0.05)
2 The correlation results of every parameter
There is a highly positive correlation between the number of VM and the number of LPPCN, the number of LPPCN cells (r=0.469, r=0.470;P=0.024, P=0.024). There is a highly positive correlation between the number of LPPCN and the number of LPPCN cells (r=0.406, P=0.011).There is a highly positive correlation between the size of tumor and the number of endothelium-dependent vessels(r=0.261, P=0.029).
3 The immunohistochemisty staining results of apoptosis-associated proteins
3.1 The expression of mitochondrial-mediating apoptosis relative proteins
3.1.1 The expression of Bcl-2 and Bax in melanoma
The expression of Bcl-2 in LPPCN-positive group was higher than LPPCN--negative group (P<0.05).The expression of Bcl-2 in SPPCN cells was higher than LPPCN cells (P<0.05). The expression of Bax in SPPCN cells was lower than LPPCN cells (P<0.05). The expression of Bcl-2 in SPPCN circum-tumors cells was lower than LPPCN circum-tumors cells (P<0.05). The expression of Bax in SPPCN circum-tumors cells was higher than LPPCN circum-tumors cells (P<0.05). The expression of Bcl-2 in LPPCN cells was lower than LPPCN circum-tumors cells (P<0.05). The expression of Bax in LPPCN cells was higher than LPPCN circum-tumors cells (P<0.05)。
3.1.2 The expression of Caspase9 and Caspase3 in melanoma
The expression of Caspase9 and Caspase3 in LPPCN cells was higher than LPPCN circum-tumors cells(P<0.05). The expression of Caspase9 and Caspase3 in LPPCN-negative group and LPPCN-positive group had not statistical significance (P>0.05).
3.2 The expression of tumor necrosis factor family-mediating apoptosis relative-proteins in melanoma
The expression of TNF, TRAIL, Fas, FasL,Caspase8 in LPPCN-negative group and LPPCN-positive group had not statistical significance(.P>0.05). The expression of TNF, TRAIL, Fas, FasL, Caspase8 in LPPCN cells and LPPCN circum-tumors cells had not statistical significance (P>0.05)
4 The expression of Twist1,MMP2,MMP-9 in melanoma
The expression of Twistl in LPPCN-positive group was higher than LPPCN-negative group (P<0.05).The expression of Twist1 in VM-positive group was higher than VM-negative group (P<0.05). The expression of Twist1 in LPPCN cells was higher than LPPCN circum-tumors cells (P<0.05).The expression of MMP-2 and MMP-9 in VM-positive group was higher than VM-negative group (P<0.05). The expression of MMP-2 in LPPCN-positive group was higher than LPPCN-negative group (P<0.05)
Conclusion:
1 VM and LPPCN existed in melanoma and the patients with VM or/and LPPCN has worse clinical prognosis than those without VM and LPPCN. The occurrence of VM and LPPCN was not correlated with age, gender, location, melanin pigment, recurrence and metastasis. The melanoma was prone to generate VM and LPPCN when its volume exceeds 20.41cm3 (diameters about 3 mm).
2 LPPCN is a transitive cells'dead way between apoptosis and necrosis. Under the genes control of mitochondrial-mediating apoptosis, some melanoma cells underwent SPPCN by hypoxic condition. SPPCN will develop LPPCN when tumor tissue lacks oxygen severely.
3 The proteins of MMP-9,MMP-2,Twist1 expressed by melanoma play a important role in VM formation. The melanoma cells could secrete PAS matter and it participates stromatic remodeling of VM.
引文
[1]Greenlee RT, Hill-Harmon MB, Murray T, et al.Cancer statistics [J].Cancer J Clin,2001,51 (1):15-36.
[2]Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma [J].Curr Probl Surg,2005,42(7):460-534.
[3]Seftor EA, Meltzer PS, Kirschmann DA, et al.Molecular determinants of human uveal melanoma invasion and metastasis[J]. Clin ExP Metastasis, 2002,19(3):233-246.
[4]Folkman J. Angiogenesis [J]. Annu Rev Med,2006,57:1-18.
[5]Eichhorn M E, Kleespies A, Angele M K. Angiogenesis in cancer:molecular mechanisms, clinical impact [J]. Langen becks Arch Surg,2007,392(3): 371-379.
[6]Folkman J.Tumor angiogenesis:therapeutie implieations [J].New Engl J Med, 1971,285 (21):1182-1186.
[7]Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].Cell,1996,86(3):353-364.
[8]Dome B, Mary J C, Hendrix, S P. Alternative Vascularization Mechanisms in Cancer, Pathology and Therapeutic Implications [J]. The American Journal of pathology,2007,170 (1),1-15.
[9]Maniotis AJ, Folberg R, Hess AR, et al. Vascular channel formation by human melanoma cells in vivo in vitro:vasculogenic mimicry [J]. Am J Pathol,1999, 155(3):739-752.
[10]Sun B,Zhang S,Zhao X,et al. Pilot Study of Molecular Mechanism on Vasculogenic Mimicry in Bi-directional Differentiated Malignant Tumors [J]. Chinese-German Journal of Clinical Oncology,2005,4(1),50-52.
[11]Chung LW, Huang WC, Sung SY, et al. Stromal-epithelial interaction in prostate cancer progression [J]. Clin Genitourin Cancer,2006,5(2):162-170.
[12]Basu GD, Pathangey LB, Tinder TL, et al. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells [J].Breast Cancer Res,2005,7(4):422-35.
[13]Hoffmeyer MR, wall KM, Dharmawardhane SF.In vitro analysis of the invasive Phenotype of SUM 149, an inflammatory breast cancer cell line[J].Cancer Cell Int,2005,5(1):11.
[14]Shirakawa K, KobayashiH, Sobajima J, et al. Inflammatory breast cancer: Vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model [J]. Breast Cancer Res,2003,5(3):136-9.
[15]Guzman G, Cotler S J, Lin AY, et al. A Pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma [J].Arch Pathol Lab Med,2007,131(12):1776-1781.
[16]Sood AK, Fletcher MS, Coffin JE,et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity [J].Am J Obstet Gynecol, 2004,190 (4):899-909.
[17]Gao Y, Zhao XL, Gu Q, et al. Correlation of vasculogenic mimicry with clinicopathologic features and prognosis of ovarian carcinoma [J]. Zhonghua Bing Li Xue Za Zhi,2009,38 (9):585-9.
[18]Sun B,Qie S,Zhang S,et al. Role and-mechanism of vasculogenic mimicry in gastrointestinal stromal tumors [J].Hum Pathol,2008,39 (3):444-451.
[19]Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma [J]. J Histochem Cytochem,2005,53(8):997-1002.
[20]Fan YZ, Sun W, Zhang WZ, et al. vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance [J]. Zhonghua Yi Xue Za Zhi, 2007,87(3):145-149.
[21]Baeten CI, Hill en F, Pauwels P,et al. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum,2009,52(12):2028-35.
[22]Li M, Gu Y, Zhang Z, Zhang S, et al. Vasculogenic Mimicry:a New prognostic Sign of Gastric Adenocarcinoma [J]. Pathol Oncol Res,2009,17.
[23]Cai XS, Jia YW, Mei J, et al.Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry [J].Chin Med J (Engl),2004,117(1):94-98.
[24]Sun B, Zhang S, Zhao X, et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas [J].Int J Oncol,2004,25 (6):1609-1614.
[25]Shiwu Zhang, Danfang Zhang, Baocun Sun. Vasculogenic mimicry:Current status and future prospects [J].Cancer Letter,2007,2(254):157-164.
[26]Hsu M, Meier F, Herlyn M. Melanoma development and progression:a conspiracy between tumor and host [J]. Differentiation,2002,70 (9):522-536.
[27]Folberg R, Maniotis AJ. Vasculogenic mimicry [J].APMIS,2004,112(7-8), 508-525.
[28]Sood AK, Fletcher MS, Hendrix MJ, et al. The embryonic-like properties of aggressive human tumor cells [J]. J Soc Gynecol Investig,2002,9(1):2-9.
[29]Seftor EA, Meltzer PS,Schatteman GC et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells:role in vasculogenic mimicry [J].Crit Rev Oncol Hematol,2002,44(1):17-27.
[30]Ramalho-Santos M, Yoon S, Matsuzaki Y, et al.Sternness:transcriptional profiling of embryonic and adult stem cells [J].Science,2002,298 (5593): 597-600.
[31]Zhang S, Guo H, Zhang D, et al. Microcirculation patterns in different stages of melanoma growth [J].Cancer Rep,2006; 15(1):15-20.
[32]Shiwu z, Man 1, Danfang, Z, et al, HyPoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma [J]. Laboratory Investigation,2009,89(5),575-586.
[33]Shiwu Zhang,Man Li, Yanjun Gu,et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma [J]. Experimental Clinical Cancer Research,2008,27(1):1-9.
[34]徐志秀,李新功,丁洪基等.免疫组化染色中消除黑色素影响的方法[J].临床与实验病理学杂志,2004,20(4)：489.
[35]Mattern, Koomagi R, Volm M, et al.Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma [J]. Br J Cancer,1996,73 (7): 931-934.
[36]Weidner N, Folkman J, Pozza F, et al.Tumor angiogenesis:a new significant and independent prognosis indicator in early-stage breast carcinoma [J].J Natl Cancer Inst,1992,84 (24):1875-1887.
[37]Hendrix MJ, Seftor EA, Hess AR et al.Vasculogenic mimicry and tumour-cell plasticity:lessons from melanoma [J].Nat Rev Cancer,2003,3 (6):411-421.
[38]Folberg R, Hendrix MJ, Maniotis AJ Vasculogenic mimicry and tumor angiogenesis [J].Am J Pathol,2000,156(2):361-381.
[39]Pisacanea A.M, Picciottob bF, M.Risio. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiationin human cutaneous melanoma [J]. Cellular Oncology,2007,29(1):59-66.
[40]C. Demirkesen, N. Buyukpinarbasili, R. Ramazanoglu,O.et al.The correlation of angiogenesis with metastasis in primary cutaneous melanoma:a comparative analysis of micro vessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor[J]. Pathology,2006,38(2):132-137.
[41]Foss AJ, Alexander RA, Hungerford JL, et al.Reassessment of the PAS patterns in uveal melanoma [J].Br J OPhthalmol,1997,81 (3):240-246.
[42]Hendrix MJ,Seftor EA,Hess AR,et al. Vasculogenic mimicry and tumor plasticity:Lessons from melanoma [J].Nat rev Cancer,2003,3(6):411-421.
[43]Hess AR, Seftor EA,Seftor RE,et al. Phosphoinositide3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63 (16):4757-4762.
[44]Sood AK, Fletcher MS, Coffin JE.et al. Functional role matrix metalloproteinases in ovarian tumor cell plasticity [J].Am J Obstet, Gynecol, 2004,190 (4):899-909.
[45]Lock shin, R.A. Zakeri, Z. Programmed cell death and apoptosis:origins of the theory [J]. Nat.Rev.Mol.CellBiol,2001,2(7),545-550.
[46]Mashima T, Tsuruo T.Defects of the apoptotic path way as therapeutic target against cancer [J].Drug Resist Updat,2005,8(6):339-343.
[47]Y Sun, Peng ZL. Programmed cell death and cancer [J].Postgrad Med J,2009, 85(1001):134-140.
[48]Hersey P. Apoptosis and melanoma:how new insights are effecting the development of new therapies for melanoma[J].Curr Opin Oncol,2006, 18(2):189-96.
[49]Gozuacik D, KimchiA. Autophagy and cell death [J]. CurrTopevBiol,2007, 78:217-45.
[50]Maiuri MC, ZalckvarE, KimchiA,etal.Self-eating and self-killing:crosstalk between autophagy and apoptosis [J].NatRev MolCellBiol,2007,8 (9):741-752.
[51]Codogno P, MeijerA J. Autophagy and signaling:their role in cell survival and cell death [J].Cell Death Differ,2005,12(Suppl.2):1509-18.
[52]Melendez A, Neufeld T P. The cell biology of autophagy in metazoans:a developing story [J]. Development,2008,135(14),2347-2360.
[53]M, Eguchi Y, et al. Acinus is a caspase3-activated protein required for apoptotic chromatin [J]. Nature,1999,401(6749):168-173.
[54]Hengartner MO.The biochemistry of apoptosis [J].Nature,2000,407(6805): 770-776.
[55]Nicotera P, Leist M and Manzo L. Neuronal cell death:a demise with different shapes [J]. Trends Pharmacol Sci,1999,20(2):46-51.
[56]Golstein P, Kroemer G. Cell death by necrosis:towards a molecular definition [J]. Trends Biochem Sci,2007,32 (1):37-43.
[57]Degterev A, Yuan J. Expansion and evolution of cell death programmes [J]. NatRev Mol Cell Bio,2008,9(5):378-90.
[58]Yuan J, LiPinski M, Degterev A. Diversity in the mechanisms of neuronal cell death [J]. Neuron,2003,40(2):401-13.
[59]Festjens N, Vanden B T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise:signalling cascades, important mediators and concomitant immune response [J]. Biochim BioPhys Acta,2006,1757(9-10):1371-1387.
[60]Vartanian AA, Burova OS, Stepanova EV, etal. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level [J]. Melanoma Res,2007,17 (6):370-9.
[61]SayersT J, Murphy W J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy [J]. Cancer Immunol Immunother,2006,55(1):76-84.
[62]Zhang P, DilleyC, MattsonMP. DNA damage responses in neural cells:Focus on telomere [J].Neuroscienee,2007,145(4):1439-1448.
[63]Er E,Oliver L,Cartron PF,et al. Mitochondria as the target of the pro-apoptotic Protein [J], Biochim BioPhys Acta.2006,1757(9-10)1301:1311.
[64]Dlugosz PJ, Billen LP, Annis MG, etal. Bcl-2 changes conformation to inhibit Bax oligomerization [J]. EMBO J,2006; 25(11):2287-2296.
[65]Belizario J.E, J. Alves.A mechanistic view of mitochondrial death decision pores. Mitochondrialores Brazilian [J]. Medical and Biological Research,2007,40(8): 1011-1024.
[66]Gursoy E, Ergin K, Bas.etal.Expression and localisation of Bcl-2 and Bax proteins in developing rat ovary [J]. Res Vet Sci,2008,84(1):56-61.
[67]Li LY, Luo X, Wang X. Endonuclease G is an apoptotic Dnase when released from mitochondria [J]. Nature,2001,412(6842):95-99.
[68]GarnettTO, FiliPPova M, Duerksen-HughesPJ.Bid is cleaved upstream of activation during TRAIL-mediated apoptosis in human osteosarcoma cells [J].Apoptosis,2007,12(7):1299-1315.
[69]GillesPie S, Borrow J, Zhang XD, Hersey P. Bim Plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells [J]. Apoptosis,2006, 11(12):2251-65.
[70]Thisse, B, el Messal, M and Perrin-Schmitt.The Twist gene:isolation of a Droso phila zygotic gene necessary for the establishment of dorsoventral pattern [J]. Nucleic Acids Res,1987,15(8):3439-3453.
[71]Jing Yang, Sendurai A. Mani, Robert A. Weinberg, Exploring a New Twist on Tumor Metastasis [J]. Cancer Res,2006,66 (9):4549-4552.
[72]Xiaomeng Zhang, Qi Wang, Ming-Tat Ling, etal.Anti-apoptotic role of TWIST and its association with akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells [J]. Int.J.Cancer,2007,120(9),1891-1898.
[73]Okamura H, Yoshida K, Haneji T.Negative regulation of TIMP1 is mediated by transcription factor TWIST1 [J]. Int J Oncol,2009,35(1):181-6.
[74]TaoSun, NanZhao, Xiu-lanZhao, et al. Expression and functional significance of twistl in hepatocellular carcinoma:Its role in vasculogenic mimicry [J]. Hepatology,2010,51(2):545-556.
[75]Hess AR, Seftor EA,Seftor RE, et al. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase(MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63(16):4757-4762.
[76]Luxia Chen, Baocun Sun, Shiwu Zhang,etal. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma [J]. Oncol Rep,2009,21(4):917-23.
[77]Handsley MM, Edwards DR.Metalloproteinases and their inhibitors in tumor angiogenesis [J].Int J Cancer,2005,115(6):849-860.
[78]Deryugina EI,Ratnikov BI,Postnova TI,et al.Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronection and enhances tyrosine phosphorylation of focal adhesion kinase [J] J Biol Chem,2002,277(12):9749-9256.
[1]Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro:vasculogenic mimicry [J]. Am J Pathol, 1999,155(3):739-752.
[2]Satyamoorthy K, Herlyn M. Melanoma Biology [J].Encyclopedia of Cancer, 2003,131-139.
[3]Sun BC, Zhang SW, Zhao XL, et al. Study on vasculogenic mimicry in malignant melanoma [J]. Zhonghua Bing Li Xue Za Zhi.2003,32 (6):539-43.
[4]Folberg R, Peer J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor of progression in primary human uveal melanoma:a matched case-control study [J].Hum Pathol,1992,23(11): 1298-1305.
[5]Konerding MA, Fait E, Dimitropoulou C, et al. Impact of fibroblast growth factor-2 on tumor microvascular architecture:a tridimensional morph metric study [J].Am J Pathol,1998,152(6):1607-1616.
[6]Potgens ALG,van Altena MC, Lubeen NH,et al. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cells lines transfected with vascular permeability factor [J].Am J Pathol,1996,148(4): 1203-1217.
[7]Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis [J]. Am J Pathol,2000,156(2):361-381.
[8]Lee Y J, Nagai N, Siar C H, et al. Angioarchitecture of primary oral malignant melanomas [J] J Histochem Cytochem,2002,50(11):1555-62.
[9]Hendrix MJ, Seftor EA, Hess AR,et al. Vasculogenic mimicry and tumor-cell plasticity:lessons from melanoma [J]. Nat Rev Cancer,2003,3(6):411-421.
[10]Sun B, Zhang D, Zhang S, et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma [J]. Cancer Lett,2007,249 (2):188-197.
[11]Sun B, Zhang S, Zhang D, et al. Doxycycline influences microcirculation patterns in B16 melanoma [J]. Exp Biol Med,2007,232 (10):1300-7.
[12]Chen L, Zhang S, Li X, et al. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model [J]. Oncol Rep. 2009,21 (4):989-94.
[13]Zhang S, Guo H, Zhang D, et al. Microcirculation patterns in different stages of melanoma growth [J].Cancer Rep,2006,15(1):15-20.
[14]Ramalho-Santos M, Yoon S, Matsuzaki Y,et al. Sternness:transcriptional profiling of embryonic and adult stem cells [J]. Science,2002, 298(5593):597-600.
[15]Sood AK, Fletcher MS, Hendrix MJ, et al. The embryonic-like properties of aggressive human tumor cells [J]. J Soc Gynecol Investig,2002,9(1):2-9.
[16]Seftor EA,Meltzer PS, Schatteman GC et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells:role in vasculogenic mimicry [J].Crit Rev Oncol Hematol,2002,44 (1):17-27.
[17]Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells:role in vasculogenic mimicry[J]. Proc Natl Acad Sci USA,2001,98 (14):8018-8023.
[18]Rufw, Seftor EA, Petrovan RJ,et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry[J].Cancer Res, 2003;63(17):5381-5389.
[19]Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling [J]. Nature,2000, 406(6795):536-540.
[20]Seftor RE, Seftor EA,et al. Cooperation interaction of laminin 5gamma2 chain, matrix metalloproteinase-2 and embryonic vasculogenesis by aggressive melanoma [J].Cancer Res,2001,61 (17):6322-6327.
[21]Sun BC, Zhang SW, Qi LS, et al. Effects of endostatin and doxycycline on microcirculation patterns in melanoma and their relevant molecular mechanisms [J]. Zhonghua Zhong Liu Za Zhi,2007,29 (7):500-4.
[22]Hendrix MJ, Seftor EA, Hess AR, et al. Molecular plasticity of human melanoma cells [J]. Oncogene,2003,22(20):3070-3075.
[23]Zhang SW, Sun BC, Zhang DF, et al. The influence of different microenvironments on melanoma invasiveness and microcirculation patterns [J]. Zhonghua Bing Li Xue Za Zhi,2007,36(12):832-7.
[24]Vartanian AA, Burova OS, Stepanova EV, et al. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level [J]. Melanoma Res, 2007,17(6):370-9.
[25]Hess AR, Seftor EA, Seftor RE, et al. Phospboinostide 3-kinase regulates membrane type1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63(16):4757-4762.
[26]Hess AR, Hendrix MJ.Focal adhesion kinase signaling and the aggressive melanoma phenotype.Cell Cycle.2006,5(5):478-80.
[27]Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation:role of epithelial cell kinase (Eck/EphA2) [J]. Cancer Res,2001,61(8):3250-3255.
[28]Hess AR, Margaryan NV, Seftor EA, et al. Deciphering the Signaling Events that promote Melanoma Tumor Cell Vasculogenic Mimicry and Their Link to Embryonic Vasculogenesis:Role of the Eph Receptors [J], Developmental Dynamics,2007,236(12):3283-3296.
[29]Lissitzky JC, Parriaux D, Ristorcelli E. etal. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro [J]. Cancer Res,2009,69(3):802-9.
[30]Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway:implications for vasculogenic mimicry [J]. Cancer Biol Ther,2006,5(2):228-233.
[31]Lissitzky JC, Parriaux D, Ristorcelli E, et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro [J]. Cancer Res,2009,69 (3):802-9.
[32]Gu XM, Li YQ, Zhao YA.Vasculogenic mimicry in the bi-directional differentiation malignant tumors of digestive tract [J]. Zhonghua Yi Xue Za Zhi, 2007 11;87(34):2398-400.
[33]Pooja Bhat, Frederick A. Jakobiec et al. Comparison of Tumor-Associated Vasculatures in Uveal and Cutaneous Melanomas [J], Seminars in Ophthalmology,2009,3 (24):166-171.
[34]Cong R, Sun Q, Yang L, et al. Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells [J]. J Exp Clin Cancer Res,2009, 28(124):1-7.
[2]Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma [J].Curr Probl Surg,2005,42(7):460-534.
[3]Seftor EA, Meltzer PS, Kirschmann DA, et al.Molecular determinants of human uveal melanoma invasion and metastasis[J]. Clin ExP Metastasis, 2002,19(3):233-246.
[4]Folkman J. Angiogenesis [J]. Annu Rev Med,2006,57:1-18.
[5]Eichhorn M E, Kleespies A, Angele M K. Angiogenesis in cancer:molecular mechanisms, clinical impact [J]. Langen becks Arch Surg,2007,392(3): 371-379.
[6]Folkman J.Tumor angiogenesis:therapeutie implieations [J].New Engl J Med, 1971,285 (21):1182-1186.
[7]Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].Cell,1996,86(3):353-364.
[8]Dome B, Mary J C, Hendrix, S P. Alternative Vascularization Mechanisms in Cancer, Pathology and Therapeutic Implications [J]. The American Journal of pathology,2007,170 (1),1-15.
[9]Maniotis AJ, Folberg R, Hess AR, et al. Vascular channel formation by human melanoma cells in vivo in vitro:vasculogenic mimicry [J]. Am J Pathol,1999, 155(3):739-752.
[10]Sun B,Zhang S,Zhao X,et al. Pilot Study of Molecular Mechanism on Vasculogenic Mimicry in Bi-directional Differentiated Malignant Tumors [J]. Chinese-German Journal of Clinical Oncology,2005,4(1),50-52.
[11]Chung LW, Huang WC, Sung SY, et al. Stromal-epithelial interaction in prostate cancer progression [J]. Clin Genitourin Cancer,2006,5(2):162-170.
[12]Basu GD, Pathangey LB, Tinder TL, et al. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells [J].Breast Cancer Res,2005,7(4):422-35.
[13]Hoffmeyer MR, wall KM, Dharmawardhane SF.In vitro analysis of the invasive Phenotype of SUM 149, an inflammatory breast cancer cell line[J].Cancer Cell Int,2005,5(1):11.
[14]Shirakawa K, KobayashiH, Sobajima J, et al. Inflammatory breast cancer: Vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model [J]. Breast Cancer Res,2003,5(3):136-9.
[15]Guzman G, Cotler S J, Lin AY, et al. A Pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma [J].Arch Pathol Lab Med,2007,131(12):1776-1781.
[16]Sood AK, Fletcher MS, Coffin JE,et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity [J].Am J Obstet Gynecol, 2004,190 (4):899-909.
[17]Gao Y, Zhao XL, Gu Q, et al. Correlation of vasculogenic mimicry with clinicopathologic features and prognosis of ovarian carcinoma [J]. Zhonghua Bing Li Xue Za Zhi,2009,38 (9):585-9.
[18]Sun B,Qie S,Zhang S,et al. Role and-mechanism of vasculogenic mimicry in gastrointestinal stromal tumors [J].Hum Pathol,2008,39 (3):444-451.
[19]Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma [J]. J Histochem Cytochem,2005,53(8):997-1002.
[20]Fan YZ, Sun W, Zhang WZ, et al. vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance [J]. Zhonghua Yi Xue Za Zhi, 2007,87(3):145-149.
[21]Baeten CI, Hill en F, Pauwels P,et al. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum,2009,52(12):2028-35.
[22]Li M, Gu Y, Zhang Z, Zhang S, et al. Vasculogenic Mimicry:a New prognostic Sign of Gastric Adenocarcinoma [J]. Pathol Oncol Res,2009,17.
[23]Cai XS, Jia YW, Mei J, et al.Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry [J].Chin Med J (Engl),2004,117(1):94-98.
[24]Sun B, Zhang S, Zhao X, et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas [J].Int J Oncol,2004,25 (6):1609-1614.
[25]Shiwu Zhang, Danfang Zhang, Baocun Sun. Vasculogenic mimicry:Current status and future prospects [J].Cancer Letter,2007,2(254):157-164.
[26]Hsu M, Meier F, Herlyn M. Melanoma development and progression:a conspiracy between tumor and host [J]. Differentiation,2002,70 (9):522-536.
[27]Folberg R, Maniotis AJ. Vasculogenic mimicry [J].APMIS,2004,112(7-8), 508-525.
[28]Sood AK, Fletcher MS, Hendrix MJ, et al. The embryonic-like properties of aggressive human tumor cells [J]. J Soc Gynecol Investig,2002,9(1):2-9.
[29]Seftor EA, Meltzer PS,Schatteman GC et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells:role in vasculogenic mimicry [J].Crit Rev Oncol Hematol,2002,44(1):17-27.
[30]Ramalho-Santos M, Yoon S, Matsuzaki Y, et al.Sternness:transcriptional profiling of embryonic and adult stem cells [J].Science,2002,298 (5593): 597-600.
[31]Zhang S, Guo H, Zhang D, et al. Microcirculation patterns in different stages of melanoma growth [J].Cancer Rep,2006; 15(1):15-20.
[32]Shiwu z, Man 1, Danfang, Z, et al, HyPoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma [J]. Laboratory Investigation,2009,89(5),575-586.
[33]Shiwu Zhang,Man Li, Yanjun Gu,et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma [J]. Experimental Clinical Cancer Research,2008,27(1):1-9.
[34]徐志秀,李新功,丁洪基等.免疫组化染色中消除黑色素影响的方法[J].临床与实验病理学杂志,2004,20(4)：489.
[35]Mattern, Koomagi R, Volm M, et al.Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma [J]. Br J Cancer,1996,73 (7): 931-934.
[36]Weidner N, Folkman J, Pozza F, et al.Tumor angiogenesis:a new significant and independent prognosis indicator in early-stage breast carcinoma [J].J Natl Cancer Inst,1992,84 (24):1875-1887.
[37]Hendrix MJ, Seftor EA, Hess AR et al.Vasculogenic mimicry and tumour-cell plasticity:lessons from melanoma [J].Nat Rev Cancer,2003,3 (6):411-421.
[38]Folberg R, Hendrix MJ, Maniotis AJ Vasculogenic mimicry and tumor angiogenesis [J].Am J Pathol,2000,156(2):361-381.
[39]Pisacanea A.M, Picciottob bF, M.Risio. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiationin human cutaneous melanoma [J]. Cellular Oncology,2007,29(1):59-66.
[40]C. Demirkesen, N. Buyukpinarbasili, R. Ramazanoglu,O.et al.The correlation of angiogenesis with metastasis in primary cutaneous melanoma:a comparative analysis of micro vessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor[J]. Pathology,2006,38(2):132-137.
[41]Foss AJ, Alexander RA, Hungerford JL, et al.Reassessment of the PAS patterns in uveal melanoma [J].Br J OPhthalmol,1997,81 (3):240-246.
[42]Hendrix MJ,Seftor EA,Hess AR,et al. Vasculogenic mimicry and tumor plasticity:Lessons from melanoma [J].Nat rev Cancer,2003,3(6):411-421.
[43]Hess AR, Seftor EA,Seftor RE,et al. Phosphoinositide3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63 (16):4757-4762.
[44]Sood AK, Fletcher MS, Coffin JE.et al. Functional role matrix metalloproteinases in ovarian tumor cell plasticity [J].Am J Obstet, Gynecol, 2004,190 (4):899-909.
[45]Lock shin, R.A. Zakeri, Z. Programmed cell death and apoptosis:origins of the theory [J]. Nat.Rev.Mol.CellBiol,2001,2(7),545-550.
[46]Mashima T, Tsuruo T.Defects of the apoptotic path way as therapeutic target against cancer [J].Drug Resist Updat,2005,8(6):339-343.
[47]Y Sun, Peng ZL. Programmed cell death and cancer [J].Postgrad Med J,2009, 85(1001):134-140.
[48]Hersey P. Apoptosis and melanoma:how new insights are effecting the development of new therapies for melanoma[J].Curr Opin Oncol,2006, 18(2):189-96.
[49]Gozuacik D, KimchiA. Autophagy and cell death [J]. CurrTopevBiol,2007, 78:217-45.
[50]Maiuri MC, ZalckvarE, KimchiA,etal.Self-eating and self-killing:crosstalk between autophagy and apoptosis [J].NatRev MolCellBiol,2007,8 (9):741-752.
[51]Codogno P, MeijerA J. Autophagy and signaling:their role in cell survival and cell death [J].Cell Death Differ,2005,12(Suppl.2):1509-18.
[52]Melendez A, Neufeld T P. The cell biology of autophagy in metazoans:a developing story [J]. Development,2008,135(14),2347-2360.
[53]M, Eguchi Y, et al. Acinus is a caspase3-activated protein required for apoptotic chromatin [J]. Nature,1999,401(6749):168-173.
[54]Hengartner MO.The biochemistry of apoptosis [J].Nature,2000,407(6805): 770-776.
[55]Nicotera P, Leist M and Manzo L. Neuronal cell death:a demise with different shapes [J]. Trends Pharmacol Sci,1999,20(2):46-51.
[56]Golstein P, Kroemer G. Cell death by necrosis:towards a molecular definition [J]. Trends Biochem Sci,2007,32 (1):37-43.
[57]Degterev A, Yuan J. Expansion and evolution of cell death programmes [J]. NatRev Mol Cell Bio,2008,9(5):378-90.
[58]Yuan J, LiPinski M, Degterev A. Diversity in the mechanisms of neuronal cell death [J]. Neuron,2003,40(2):401-13.
[59]Festjens N, Vanden B T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise:signalling cascades, important mediators and concomitant immune response [J]. Biochim BioPhys Acta,2006,1757(9-10):1371-1387.
[60]Vartanian AA, Burova OS, Stepanova EV, etal. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level [J]. Melanoma Res,2007,17 (6):370-9.
[61]SayersT J, Murphy W J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy [J]. Cancer Immunol Immunother,2006,55(1):76-84.
[62]Zhang P, DilleyC, MattsonMP. DNA damage responses in neural cells:Focus on telomere [J].Neuroscienee,2007,145(4):1439-1448.
[63]Er E,Oliver L,Cartron PF,et al. Mitochondria as the target of the pro-apoptotic Protein [J], Biochim BioPhys Acta.2006,1757(9-10)1301:1311.
[64]Dlugosz PJ, Billen LP, Annis MG, etal. Bcl-2 changes conformation to inhibit Bax oligomerization [J]. EMBO J,2006; 25(11):2287-2296.
[65]Belizario J.E, J. Alves.A mechanistic view of mitochondrial death decision pores. Mitochondrialores Brazilian [J]. Medical and Biological Research,2007,40(8): 1011-1024.
[66]Gursoy E, Ergin K, Bas.etal.Expression and localisation of Bcl-2 and Bax proteins in developing rat ovary [J]. Res Vet Sci,2008,84(1):56-61.
[67]Li LY, Luo X, Wang X. Endonuclease G is an apoptotic Dnase when released from mitochondria [J]. Nature,2001,412(6842):95-99.
[68]GarnettTO, FiliPPova M, Duerksen-HughesPJ.Bid is cleaved upstream of activation during TRAIL-mediated apoptosis in human osteosarcoma cells [J].Apoptosis,2007,12(7):1299-1315.
[69]GillesPie S, Borrow J, Zhang XD, Hersey P. Bim Plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells [J]. Apoptosis,2006, 11(12):2251-65.
[70]Thisse, B, el Messal, M and Perrin-Schmitt.The Twist gene:isolation of a Droso phila zygotic gene necessary for the establishment of dorsoventral pattern [J]. Nucleic Acids Res,1987,15(8):3439-3453.
[71]Jing Yang, Sendurai A. Mani, Robert A. Weinberg, Exploring a New Twist on Tumor Metastasis [J]. Cancer Res,2006,66 (9):4549-4552.
[72]Xiaomeng Zhang, Qi Wang, Ming-Tat Ling, etal.Anti-apoptotic role of TWIST and its association with akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells [J]. Int.J.Cancer,2007,120(9),1891-1898.
[73]Okamura H, Yoshida K, Haneji T.Negative regulation of TIMP1 is mediated by transcription factor TWIST1 [J]. Int J Oncol,2009,35(1):181-6.
[74]TaoSun, NanZhao, Xiu-lanZhao, et al. Expression and functional significance of twistl in hepatocellular carcinoma:Its role in vasculogenic mimicry [J]. Hepatology,2010,51(2):545-556.
[75]Hess AR, Seftor EA,Seftor RE, et al. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase(MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63(16):4757-4762.
[76]Luxia Chen, Baocun Sun, Shiwu Zhang,etal. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma [J]. Oncol Rep,2009,21(4):917-23.
[77]Handsley MM, Edwards DR.Metalloproteinases and their inhibitors in tumor angiogenesis [J].Int J Cancer,2005,115(6):849-860.
[78]Deryugina EI,Ratnikov BI,Postnova TI,et al.Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronection and enhances tyrosine phosphorylation of focal adhesion kinase [J] J Biol Chem,2002,277(12):9749-9256.
[1]Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro:vasculogenic mimicry [J]. Am J Pathol, 1999,155(3):739-752.
[2]Satyamoorthy K, Herlyn M. Melanoma Biology [J].Encyclopedia of Cancer, 2003,131-139.
[3]Sun BC, Zhang SW, Zhao XL, et al. Study on vasculogenic mimicry in malignant melanoma [J]. Zhonghua Bing Li Xue Za Zhi.2003,32 (6):539-43.
[4]Folberg R, Peer J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor of progression in primary human uveal melanoma:a matched case-control study [J].Hum Pathol,1992,23(11): 1298-1305.
[5]Konerding MA, Fait E, Dimitropoulou C, et al. Impact of fibroblast growth factor-2 on tumor microvascular architecture:a tridimensional morph metric study [J].Am J Pathol,1998,152(6):1607-1616.
[6]Potgens ALG,van Altena MC, Lubeen NH,et al. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cells lines transfected with vascular permeability factor [J].Am J Pathol,1996,148(4): 1203-1217.
[7]Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis [J]. Am J Pathol,2000,156(2):361-381.
[8]Lee Y J, Nagai N, Siar C H, et al. Angioarchitecture of primary oral malignant melanomas [J] J Histochem Cytochem,2002,50(11):1555-62.
[9]Hendrix MJ, Seftor EA, Hess AR,et al. Vasculogenic mimicry and tumor-cell plasticity:lessons from melanoma [J]. Nat Rev Cancer,2003,3(6):411-421.
[10]Sun B, Zhang D, Zhang S, et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma [J]. Cancer Lett,2007,249 (2):188-197.
[11]Sun B, Zhang S, Zhang D, et al. Doxycycline influences microcirculation patterns in B16 melanoma [J]. Exp Biol Med,2007,232 (10):1300-7.
[12]Chen L, Zhang S, Li X, et al. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model [J]. Oncol Rep. 2009,21 (4):989-94.
[13]Zhang S, Guo H, Zhang D, et al. Microcirculation patterns in different stages of melanoma growth [J].Cancer Rep,2006,15(1):15-20.
[14]Ramalho-Santos M, Yoon S, Matsuzaki Y,et al. Sternness:transcriptional profiling of embryonic and adult stem cells [J]. Science,2002, 298(5593):597-600.
[15]Sood AK, Fletcher MS, Hendrix MJ, et al. The embryonic-like properties of aggressive human tumor cells [J]. J Soc Gynecol Investig,2002,9(1):2-9.
[16]Seftor EA,Meltzer PS, Schatteman GC et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells:role in vasculogenic mimicry [J].Crit Rev Oncol Hematol,2002,44 (1):17-27.
[17]Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells:role in vasculogenic mimicry[J]. Proc Natl Acad Sci USA,2001,98 (14):8018-8023.
[18]Rufw, Seftor EA, Petrovan RJ,et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry[J].Cancer Res, 2003;63(17):5381-5389.
[19]Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling [J]. Nature,2000, 406(6795):536-540.
[20]Seftor RE, Seftor EA,et al. Cooperation interaction of laminin 5gamma2 chain, matrix metalloproteinase-2 and embryonic vasculogenesis by aggressive melanoma [J].Cancer Res,2001,61 (17):6322-6327.
[21]Sun BC, Zhang SW, Qi LS, et al. Effects of endostatin and doxycycline on microcirculation patterns in melanoma and their relevant molecular mechanisms [J]. Zhonghua Zhong Liu Za Zhi,2007,29 (7):500-4.
[22]Hendrix MJ, Seftor EA, Hess AR, et al. Molecular plasticity of human melanoma cells [J]. Oncogene,2003,22(20):3070-3075.
[23]Zhang SW, Sun BC, Zhang DF, et al. The influence of different microenvironments on melanoma invasiveness and microcirculation patterns [J]. Zhonghua Bing Li Xue Za Zhi,2007,36(12):832-7.
[24]Vartanian AA, Burova OS, Stepanova EV, et al. Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level [J]. Melanoma Res, 2007,17(6):370-9.
[25]Hess AR, Seftor EA, Seftor RE, et al. Phospboinostide 3-kinase regulates membrane type1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry [J].Cancer Res,2003,63(16):4757-4762.
[26]Hess AR, Hendrix MJ.Focal adhesion kinase signaling and the aggressive melanoma phenotype.Cell Cycle.2006,5(5):478-80.
[27]Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation:role of epithelial cell kinase (Eck/EphA2) [J]. Cancer Res,2001,61(8):3250-3255.
[28]Hess AR, Margaryan NV, Seftor EA, et al. Deciphering the Signaling Events that promote Melanoma Tumor Cell Vasculogenic Mimicry and Their Link to Embryonic Vasculogenesis:Role of the Eph Receptors [J], Developmental Dynamics,2007,236(12):3283-3296.
[29]Lissitzky JC, Parriaux D, Ristorcelli E. etal. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro [J]. Cancer Res,2009,69(3):802-9.
[30]Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway:implications for vasculogenic mimicry [J]. Cancer Biol Ther,2006,5(2):228-233.
[31]Lissitzky JC, Parriaux D, Ristorcelli E, et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro [J]. Cancer Res,2009,69 (3):802-9.
[32]Gu XM, Li YQ, Zhao YA.Vasculogenic mimicry in the bi-directional differentiation malignant tumors of digestive tract [J]. Zhonghua Yi Xue Za Zhi, 2007 11;87(34):2398-400.
[33]Pooja Bhat, Frederick A. Jakobiec et al. Comparison of Tumor-Associated Vasculatures in Uveal and Cutaneous Melanomas [J], Seminars in Ophthalmology,2009,3 (24):166-171.
[34]Cong R, Sun Q, Yang L, et al. Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells [J]. J Exp Clin Cancer Res,2009, 28(124):1-7.